Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TPST files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Governance Amendment Failed to Reach 75% Approval Threshold (new) — The high bar for approval and insufficient initial support suggests potential stockholder resistance or apathy toward the proposed governance changes.
Tempest adjourns special meeting to Aug 17 after governance amendment fails to reach 75% threshold
Filed July 28, 2026 · Period ending July 27, 2026 · ~1 min read
Key Changes
-
medium
Special meeting adjourned after governance amendment requiring 75% supermajority did not receive sufficient votes despite 67.7% quorum (10.0M of 14.8M shares represented)
Item 8.01 — Other Events verify on EDGAR → -
medium
Proposal would eliminate supermajority voting requirements and permit stockholder action by written consent, shifting toward more stockholder-friendly governance
Item 8.01 — Other Events verify on EDGAR → -
low
Meeting reconvenes Aug 17, 2026 at 12:00 p.m. ET; company engaged Sodali & Co. to assist with proxy solicitation and increase participation
Item 8.01 — Other Events verify on EDGAR →
Summary
Tempest Therapeutics held a special meeting on July 27, 2026 to vote on a charter amendment that would eliminate certain supermajority voting requirements and allow stockholders to take action by written consent. Despite achieving quorum with 67.7% of outstanding shares represented (10.0 million of 14.8 million shares), the proposal did not receive the 75% supermajority required for approval. The company adjourned the meeting to August 17, 2026 to provide additional time for stockholders to vote and has engaged proxy solicitation firm Sodali & Co. to increase participation.
The governance changes would make it easier for stockholders to influence company decisions by lowering voting thresholds and providing mechanisms for action outside formal meetings. The failure to reach the 75% threshold on the first attempt raises questions about stockholder support for the changes or engagement levels. Investors should watch whether the company can secure sufficient votes at the reconvened meeting and what the final approval margin reveals about stockholder sentiment on governance matters.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Tempest Therapeutics disclosed submission of matters to a shareholder vote, but the filing body is incomplete or truncated.
Added in current filing · verify on EDGAR →
Item 5.07
Submission of Matters to a Vote of Security Holders.
The information disclosed in
The 8-K indicates that matters were submitted to a shareholder vote under Item 5.07, but the filing text is incomplete or truncated. The disclosure does not provide vote results, proposals voted on, or any substantive information about the shareholder meeting. Investors cannot assess what was voted on or the outcomes without the complete filing.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
convened its special meeting of stockholders (the “Special Meeting”) for the purpose of approving a Certificate of Amendment to the Company’s Restated Certificate of Incorporation to replace specified supermajority voting requirements and permit stockholder action by written consent
The proposal being voted on would amend the company's charter to eliminate certain supermajority voting requirements and allow stockholders to take action by written consent rather than requiring formal meetings. This represents a shift toward more stockholder-friendly governance by lowering voting thresholds and providing additional mechanisms for stockholder action.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Company has also engaged Sodali & Co., a proxy solicitation firm to assist with obtaining adequate votes to achieve the required quorum of a majority of the outstanding shares of the Company’s common stock entitled to vote at the Special Meeting.
The company has hired Sodali & Co., a professional proxy solicitation firm, to help secure sufficient votes for the reconvened meeting. This indicates the company is actively working to increase participation and achieve the 75% approval threshold needed to pass the governance amendment.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 28, 2026 · How we verify